-
1
-
-
84908398480
-
Biochemical phenotype of a common disease-causing mutation and a possible therapeutic approach for the phosphomannomutase 2-associated disorder of glycosylation
-
Andreotti G, Pedone E, Giordano A, Cubellis MV. 2013. Biochemical phenotype of a common disease-causing mutation and a possible therapeutic approach for the phosphomannomutase 2-associated disorder of glycosylation. Mol Genet Genomic Med 1:32–44.
-
(2013)
Mol Genet Genomic Med
, vol.1
, pp. 32-44
-
-
Andreotti, G.1
Pedone, E.2
Giordano, A.3
Cubellis, M.V.4
-
2
-
-
84900131626
-
Pharmacological chaperones for enzyme enhancement therapy in genetic diseases
-
Aymami J, Barril X, Rodriguez-Pascau L, Martinell M. 2013. Pharmacological chaperones for enzyme enhancement therapy in genetic diseases. Pharm Pat Anal 2:109–124.
-
(2013)
Pharm Pat Anal
, vol.2
, pp. 109-124
-
-
Aymami, J.1
Barril, X.2
Rodriguez-Pascau, L.3
Martinell, M.4
-
3
-
-
84908530414
-
Chemistry: Chemical con artists foil drug discovery
-
Baell J, Walters MA. 2014. Chemistry: Chemical con artists foil drug discovery. Nature 513:481–483.
-
(2014)
Nature
, vol.513
, pp. 481-483
-
-
Baell, J.1
Walters, M.A.2
-
4
-
-
77950571108
-
New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays
-
Baell JB, Holloway GA. 2010. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 53:2719–2740.
-
(2010)
J Med Chem
, vol.53
, pp. 2719-2740
-
-
Baell, J.B.1
Holloway, G.A.2
-
5
-
-
33846078171
-
Identification and evaluation of molecular properties related to preclinical optimization and clinical fate
-
Blake JF. 2005. Identification and evaluation of molecular properties related to preclinical optimization and clinical fate. Med Chem 1:649–655.
-
(2005)
Med Chem
, vol.1
, pp. 649-655
-
-
Blake, J.F.1
-
6
-
-
0017184389
-
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
-
Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254.
-
(1976)
Anal Biochem
, vol.72
, pp. 248-254
-
-
Bradford, M.M.1
-
7
-
-
84862234023
-
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade
-
-
Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudinière R. 2012. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 109:9629–9634.
-
(2012)
Proc Natl Acad Sci USA
, vol.109
, pp. 9629-9634
-
-
Bulawa, C.E.1
Connelly, S.2
Devit, M.3
Wang, L.4
Weigel, C.5
Fleming, J.A.6
Packman, J.7
Powers, E.T.8
Wiseman, R.L.9
Foss, T.R.10
Wilson, I.A.11
Kelly, J.W.12
Labaudinière, R.13
-
8
-
-
84862023493
-
Chemical and biological properties of frequent screening hits
-
Che J, King FJ, Zhou B, Zhou Y. 2012. Chemical and biological properties of frequent screening hits. J Chem Inf Model 52:913–926.
-
(2012)
J Chem Inf Model
, vol.52
, pp. 913-926
-
-
Che, J.1
King, F.J.2
Zhou, B.3
Zhou, Y.4
-
9
-
-
84924692170
-
PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS
-
Dahlin JL, Nissink JW, Strasser JM, Francis S, Higgins L, Zhou H, Zhang Z, Walters MA. 2015. PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS. J Med Chem 58:2091–2113.
-
(2015)
J Med Chem
, vol.58
, pp. 2091-2113
-
-
Dahlin, J.L.1
Nissink, J.W.2
Strasser, J.M.3
Francis, S.4
Higgins, L.5
Zhou, H.6
Zhang, Z.7
Walters, M.A.8
-
10
-
-
84906764097
-
The essential roles of chemistry in high-throughput screening triage
-
Dahlin JL, Walters MA. 2014. The essential roles of chemistry in high-throughput screening triage. Future Med Chem 6:1265–1290.
-
(2014)
Future Med Chem
, vol.6
, pp. 1265-1290
-
-
Dahlin, J.L.1
Walters, M.A.2
-
11
-
-
0032492583
-
A novel disorder of N-glycosylation due to phosphomannose isomerase deficiency
-
de Koning TJ, Dorland L, van Diggelen OP, Boonman AM, de Jong GJ, van Noort WL, De Schryver J, Duran M, van den Berg IE, Gerwig GJ et al. 1998. A novel disorder of N-glycosylation due to phosphomannose isomerase deficiency. Biochem Biophys Res Commun 245:38–42.
-
(1998)
Biochem Biophys Res Commun
, vol.245
, pp. 38-42
-
-
de Koning, T.J.1
Dorland, L.2
van Diggelen, O.P.3
Boonman, A.M.4
de Jong, G.J.5
van Noort, W.L.6
De Schryver, J.7
Duran, M.8
van den Berg, I.E.9
Gerwig, G.J.10
-
12
-
-
0036895451
-
Enzyme replacement and enhancement therapies: lessons from lysosomal disorders
-
Desnick RJ, Schuchman EH. 2002. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet 3:954–966.
-
(2002)
Nat Rev Genet
, vol.3
, pp. 954-966
-
-
Desnick, R.J.1
Schuchman, E.H.2
-
13
-
-
37349013379
-
A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity
-
Fan JQ. 2008. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity. Biol Chem 389:1–11.
-
(2008)
Biol Chem
, vol.389
, pp. 1-11
-
-
Fan, J.Q.1
-
14
-
-
70249111204
-
Towards a therapy for phosphomannomutase 2 deficiency, the defect in CDG-Ia patients
-
Freeze HH. 2009. Towards a therapy for phosphomannomutase 2 deficiency, the defect in CDG-Ia patients. Biochim Biophys Acta 1792:835–840.
-
(2009)
Biochim Biophys Acta
, vol.1792
, pp. 835-840
-
-
Freeze, H.H.1
-
15
-
-
84893734160
-
Solving glycosylation disorders: fundamental approaches reveal complicated pathways
-
Freeze HH, Chong JX, Bamshad MJ, Ng BG. 2014. Solving glycosylation disorders: fundamental approaches reveal complicated pathways. Am J Hum Genet 94:161–175.
-
(2014)
Am J Hum Genet
, vol.94
, pp. 161-175
-
-
Freeze, H.H.1
Chong, J.X.2
Bamshad, M.J.3
Ng, B.G.4
-
16
-
-
84871650725
-
Small molecules that target protein misfolding
-
Gavrin LK, Denny RA, Saiah E. 2012. Small molecules that target protein misfolding. J Med Chem 55:10823–10843.
-
(2012)
J Med Chem
, vol.55
, pp. 10823-10843
-
-
Gavrin, L.K.1
Denny, R.A.2
Saiah, E.3
-
17
-
-
70349089028
-
The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia)
-
Grunewald S. 2009. The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia). Biochim Biophys Acta 1792:827–834.
-
(2009)
Biochim Biophys Acta
, vol.1792
, pp. 827-834
-
-
Grunewald, S.1
-
18
-
-
0035125320
-
High residual activity of PMM2 in patients' fibroblasts: possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency)
-
Grunewald S, Schollen E, Van Schaftingen E, Jaeken J, Matthijs G. 2001. High residual activity of PMM2 in patients' fibroblasts: possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency). Am J Hum Genet 68:347–354.
-
(2001)
Am J Hum Genet
, vol.68
, pp. 347-354
-
-
Grunewald, S.1
Schollen, E.2
Van Schaftingen, E.3
Jaeken, J.4
Matthijs, G.5
-
19
-
-
0033194752
-
Strategic pooling of compounds for high-throughput screening
-
Hann M, Hudson B, Lewell X, Lifely R, Miller L, Ramsden N. 1999. Strategic pooling of compounds for high-throughput screening. J Chem Inf Comput Sci 39:897–902.
-
(1999)
J Chem Inf Comput Sci
, vol.39
, pp. 897-902
-
-
Hann, M.1
Hudson, B.2
Lewell, X.3
Lifely, R.4
Miller, L.5
Ramsden, N.6
-
20
-
-
11844253252
-
ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens
-
Huth JR, Mendoza R, Olejniczak ET, Johnson RW, Cothron DA, Liu Y, Lerner CG, Chen J, Hajduk PJ. 2005. ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens. J Am Chem Soc 127:217–224.
-
(2005)
J Am Chem Soc
, vol.127
, pp. 217-224
-
-
Huth, J.R.1
Mendoza, R.2
Olejniczak, E.T.3
Johnson, R.W.4
Cothron, D.A.5
Liu, Y.6
Lerner, C.G.7
Chen, J.8
Hajduk, P.J.9
-
21
-
-
78650401291
-
Congenital disorders of glycosylation
-
Jaeken J. 2010. Congenital disorders of glycosylation. Ann NY Acad Sci 1214:190–198.
-
(2010)
Ann NY Acad Sci
, vol.1214
, pp. 190-198
-
-
Jaeken, J.1
-
22
-
-
84882931235
-
Pharmacological chaperones as a potential therapeutic option in methylmalonic aciduria cblB type
-
Jorge-Finnigan A, Brasil S, Underhaug J, Ruiz-Sala P, Merinero B, Banerjee R, Desviat LR, Ugarte M, Martinez A, Perez B. 2013. Pharmacological chaperones as a potential therapeutic option in methylmalonic aciduria cblB type. Hum Mol Genet 22:3680–3689.
-
(2013)
Hum Mol Genet
, vol.22
, pp. 3680-3689
-
-
Jorge-Finnigan, A.1
Brasil, S.2
Underhaug, J.3
Ruiz-Sala, P.4
Merinero, B.5
Banerjee, R.6
Desviat, L.R.7
Ugarte, M.8
Martinez, A.9
Perez, B.10
-
23
-
-
34547697475
-
Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study
-
Levy HL, Milanowski A, Chakrapani A, Cleary M, Lee P, Trefz FK, Whitley CB, Feillet F, Feigenbaum AS, Bebchuk JD et al. 2007. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 370:504–510.
-
(2007)
Lancet
, vol.370
, pp. 504-510
-
-
Levy, H.L.1
Milanowski, A.2
Chakrapani, A.3
Cleary, M.4
Lee, P.5
Trefz, F.K.6
Whitley, C.B.7
Feillet, F.8
Feigenbaum, A.S.9
Bebchuk, J.D.10
-
24
-
-
0033736282
-
Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia)
-
Matthijs G, Schollen E, Bjursell C, Erlandson A, Freeze H, Imtiaz F, Kjaergaard S, Martinsson T, Schwartz M, Seta N et al. 2000. Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia). Hum Mutat 16:386–394.
-
(2000)
Hum Mutat
, vol.16
, pp. 386-394
-
-
Matthijs, G.1
Schollen, E.2
Bjursell, C.3
Erlandson, A.4
Freeze, H.5
Imtiaz, F.6
Kjaergaard, S.7
Martinsson, T.8
Schwartz, M.9
Seta, N.10
-
25
-
-
50249175120
-
Chemical and biological approaches synergize to ameliorate protein-folding diseases
-
Mu TW, Ong DS, Wang YJ, Balch WE, Yates JR, 3rd, Segatori L, Kelly JW. 2008. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 134:769–781.
-
(2008)
Cell
, vol.134
, pp. 769-781
-
-
Mu, T.W.1
Ong, D.S.2
Wang, Y.J.3
Balch, W.E.4
Yates, J.R.5
Segatori, S.L.6
Kelly, J.W.7
-
26
-
-
84904099631
-
Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators
-
Muntau AC, Leandro J, Staudigl M, Mayer F, Gersting SW. 2014. Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators. J Inherit Metab Dis 37:505–523.
-
(2014)
J Inherit Metab Dis
, vol.37
, pp. 505-523
-
-
Muntau, A.C.1
Leandro, J.2
Staudigl, M.3
Mayer, F.4
Gersting, S.W.5
-
27
-
-
37249005205
-
The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability
-
Niesen FH, Berglund H, Vedadi M. 2007. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc 2:2212–2221.
-
(2007)
Nat Protoc
, vol.2
, pp. 2212-2221
-
-
Niesen, F.H.1
Berglund, H.2
Vedadi, M.3
-
28
-
-
0012286670
-
Pharmacokinetically based mapping device for chemical space navigation
-
Oprea TI, Zamora I, Ungell AL. 2002. Pharmacokinetically based mapping device for chemical space navigation. J Comb Chem 4:258–266.
-
(2002)
J Comb Chem
, vol.4
, pp. 258-266
-
-
Oprea, T.I.1
Zamora, I.2
Ungell, A.L.3
-
29
-
-
84906248420
-
Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development
-
Panicker LM, Miller D, Awad O, Bose V, Lun Y, Park TS, Zambidis ET, Sgambato JA, Feldman RA. 2014. Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development. Stem Cells 32:2338–2349.
-
(2014)
Stem Cells
, vol.32
, pp. 2338-2349
-
-
Panicker, L.M.1
Miller, D.2
Awad, O.3
Bose, V.4
Lun, Y.5
Park, T.S.6
Zambidis, E.T.7
Sgambato, J.A.8
Feldman, R.A.9
-
30
-
-
84904705105
-
The molecular landscape of phosphomannose mutase deficiency in iberian peninsula: identification of 15 population-specific mutations
-
Perez B, Briones P, Quelhas D, Artuch R, Vega AI, Quintana E, Gort L, Ecay MJ, Matthijs G, Ugarte M et al. 2011. The molecular landscape of phosphomannose mutase deficiency in iberian peninsula: identification of 15 population-specific mutations. JIMD Rep 1:117–123.
-
(2011)
JIMD Rep
, vol.1
, pp. 117-123
-
-
Perez, B.1
Briones, P.2
Quelhas, D.3
Artuch, R.4
Vega, A.I.5
Quintana, E.6
Gort, L.7
Ecay, M.J.8
Matthijs, G.9
Ugarte, M.10
-
31
-
-
0037242342
-
Phenylketonuria: genotype-phenotype correlations based on expression analysis of structural and functional mutations in PAH
-
Pey AL, Desviat LR, Gamez A, Ugarte M, Perez B. 2003. Phenylketonuria: genotype-phenotype correlations based on expression analysis of structural and functional mutations in PAH. Hum Mutat 21:370–378.
-
(2003)
Hum Mutat
, vol.21
, pp. 370-378
-
-
Pey, A.L.1
Desviat, L.R.2
Gamez, A.3
Ugarte, M.4
Perez, B.5
-
32
-
-
48749132287
-
Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria
-
Pey AL, Ying M, Cremades N, Velazquez-Campoy A, Scherer T, Thony B, Sancho J, Martinez A. 2008. Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. J Clin Invest 118:2858–2867.
-
(2008)
J Clin Invest
, vol.118
, pp. 2858-2867
-
-
Pey, A.L.1
Ying, M.2
Cremades, N.3
Velazquez-Campoy, A.4
Scherer, T.5
Thony, B.6
Sancho, J.7
Martinez, A.8
-
33
-
-
67650410543
-
Biological and chemical approaches to diseases of proteostasis deficiency
-
Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE. 2009. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 78:959–991.
-
(2009)
Annu Rev Biochem
, vol.78
, pp. 959-991
-
-
Powers, E.T.1
Morimoto, R.I.2
Dillin, A.3
Kelly, J.W.4
Balch, W.E.5
-
34
-
-
84855555842
-
Successful prenatal mannose treatment for congenital disorder of glycosylation-Ia in mice
-
Schneider A, Thiel C, Rindermann J, DeRossi C, Popovici D, Hoffmann GF, Grone HJ, Korner C. 2012. Successful prenatal mannose treatment for congenital disorder of glycosylation-Ia in mice. Nat Med 18:71–73.
-
(2012)
Nat Med
, vol.18
, pp. 71-73
-
-
Schneider, A.1
Thiel, C.2
Rindermann, J.3
DeRossi, C.4
Popovici, D.5
Hoffmann, G.F.6
Grone, H.J.7
Korner, C.8
-
35
-
-
0034082327
-
Lack of Hardy-Weinberg equilibrium for the most prevalent PMM2 mutation in CDG-Ia (congenital disorders of glycosylation type Ia)
-
Schollen E, Kjaergaard S, Legius E, Schwartz M, Matthijs G. 2000. Lack of Hardy-Weinberg equilibrium for the most prevalent PMM2 mutation in CDG-Ia (congenital disorders of glycosylation type Ia). Eur J Hum Genet 8:367–371.
-
(2000)
Eur J Hum Genet
, vol.8
, pp. 367-371
-
-
Schollen, E.1
Kjaergaard, S.2
Legius, E.3
Schwartz, M.4
Matthijs, G.5
-
36
-
-
84945249873
-
Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment
-
Serrano M, de Diego V, Muchart J, Cuadras D, Felipe A, Macaya A, Velazquez R, Poo MP, Fons C, O'Callaghan MM et al. 2015. Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment. Orphanet J Rare Dis 10:138.
-
(2015)
Orphanet J Rare Dis
, vol.10
, pp. 138
-
-
Serrano, M.1
de Diego, V.2
Muchart, J.3
Cuadras, D.4
Felipe, A.5
Macaya, A.6
Velazquez, R.7
Poo, M.P.8
Fons, C.9
O'Callaghan, M.M.10
-
37
-
-
80655144748
-
Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts
-
Sharma V, Ichikawa M, He P, Scott DA, Bravo Y, Dahl R, Ng BG, Cosford ND, Freeze HH. 2011. Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts. J Biol Chem 286:39431–39438.
-
(2011)
J Biol Chem
, vol.286
, pp. 39431-39438
-
-
Sharma, V.1
Ichikawa, M.2
He, P.3
Scott, D.A.4
Bravo, Y.5
Dahl, R.6
Ng, B.G.7
Cosford, N.D.8
Freeze, H.H.9
-
38
-
-
84891837451
-
The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine
-
Stenson PD, Mort M, Ball EV, Shaw K, Phillips A, Cooper DN. 2014. The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet 133:1–9.
-
(2014)
Hum Genet
, vol.133
, pp. 1-9
-
-
Stenson, P.D.1
Mort, M.2
Ball, E.V.3
Shaw, K.4
Phillips, A.5
Cooper, D.N.6
-
39
-
-
79952035065
-
Rescue of misfolded proteins and stabilization by small molecules
-
Stevens RC, Sancho J, Martinez A. 2010. Rescue of misfolded proteins and stabilization by small molecules. Methods Mol Biol 648:313–324.
-
(2010)
Methods Mol Biol
, vol.648
, pp. 313-324
-
-
Stevens, R.C.1
Sancho, J.2
Martinez, A.3
-
40
-
-
14844294424
-
Protein production by auto-induction in high density shaking cultures
-
Studier FW. 2005. Protein production by auto-induction in high density shaking cultures. Protein Expr Purif 41:207–234.
-
(2005)
Protein Expr Purif
, vol.41
, pp. 207-234
-
-
Studier, F.W.1
-
41
-
-
34250744722
-
Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction
-
Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, Jeffrey P. 2007. Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 322:205–213.
-
(2007)
J Pharmacol Exp Ther
, vol.322
, pp. 205-213
-
-
Summerfield, S.G.1
Read, K.2
Begley, D.J.3
Obradovic, T.4
Hidalgo, I.J.5
Coggon, S.6
Lewis, A.V.7
Porter, R.A.8
Jeffrey, P.9
-
42
-
-
33746578432
-
Targeted disruption of the mouse phosphomannomutase 2 gene causes early embryonic lethality
-
Thiel C, Lubke T, Matthijs G, von Figura K, Korner C. 2006. Targeted disruption of the mouse phosphomannomutase 2 gene causes early embryonic lethality. Mol Cell Biol 26:5615–5620.
-
(2006)
Mol Cell Biol
, vol.26
, pp. 5615-5620
-
-
Thiel, C.1
Lubke, T.2
Matthijs, G.3
von Figura, K.4
Korner, C.5
-
43
-
-
84873040393
-
Neuronopathic Gaucher's disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds
-
Tiscornia G, Vivas EL, Matalonga L, Berniakovich I, Barragan Monasterio M, Eguizabal C, Gort L, Gonzalez F, Ortiz Mellet C, Garcia Fernandez JM et al. 2013. Neuronopathic Gaucher's disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds. Hum Mol Genet 22:633–645.
-
(2013)
Hum Mol Genet
, vol.22
, pp. 633-645
-
-
Tiscornia, G.1
Vivas, E.L.2
Matalonga, L.3
Berniakovich, I.4
Barragan Monasterio, M.5
Eguizabal, C.6
Gort, L.7
Gonzalez, F.8
Ortiz Mellet, C.9
Garcia Fernandez, J.M.10
-
44
-
-
84862859338
-
Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation
-
Tomasic T, Peterlin Masic L. 2012. Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation. Expert Opin Drug Discov 7:549–560.
-
(2012)
Expert Opin Drug Discov
, vol.7
, pp. 549-560
-
-
Tomasic, T.1
Peterlin Masic, L.2
-
45
-
-
0029585865
-
Phosphomannomutase deficiency is a cause of carbohydrate-deficient glycoprotein syndrome type I
-
Van Schaftingen E, Jaeken J. 1995. Phosphomannomutase deficiency is a cause of carbohydrate-deficient glycoprotein syndrome type I. FEBS Lett 377:318–320.
-
(1995)
FEBS Lett
, vol.377
, pp. 318-320
-
-
Van Schaftingen, E.1
Jaeken, J.2
-
46
-
-
66749140994
-
Functional analysis of three splicing mutations identified in the PMM2 gene: toward a new therapy for congenital disorder of glycosylation type Ia
-
Vega AI, Perez-Cerda C, Desviat LR, Matthijs G, Ugarte M, Perez B. 2009. Functional analysis of three splicing mutations identified in the PMM2 gene: toward a new therapy for congenital disorder of glycosylation type Ia. Hum Mutat 30:795–803.
-
(2009)
Hum Mutat
, vol.30
, pp. 795-803
-
-
Vega, A.I.1
Perez-Cerda, C.2
Desviat, L.R.3
Matthijs, G.4
Ugarte, M.5
Perez, B.6
-
47
-
-
84938973394
-
The effects of PMM2-CDG-causing mutations on the folding, activity, and stability of the PMM2 protein
-
36851860
-
Yuste-Checa P, Gamez A, Brasil S, Desviat LR, Ugarte M, Perez-Cerda C, Perez B. 2015. The effects of PMM2-CDG-causing mutations on the folding, activity, and stability of the PMM2 protein. Hum Mutat 36:851:860.
-
(2015)
Hum Mutat
-
-
Yuste-Checa, P.1
Gamez, A.2
Brasil, S.3
Desviat, L.R.4
Ugarte, M.5
Perez-Cerda, C.6
Perez, B.7
|